European Union - English - EMA (European Medicines Agency)

intervet international b.v. - inactivated leptospira strains: l. interrogans serogroup canicola serovar portland-vere (strain ca-12-000); l. interrogans serogroup icterohaemorrhagiae serovar copenhageni (strain ic-02-001); l. interrogans serogroup australis serovar bratislava (strain as-05-073); l. kirschneri serogroup grippotyphosa serovar dadas (strain gr-01-005) - immunologicals for canidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - dogs - for active immunisation of dogs against:l. interrogans serogroup canicola serovar canicola to reduce infection and urinary excretion;l. interrogans serogroup icterohaemorrhagiae serovar copenhageni to reduce infection and urinary excretion;l. interrogans serogroup australis serovar bratislava to reduce infection;l. kirschneri serogroup grippotyphosa serovar bananal/lianguang to reduce infection and urinary excretion.

European Union - English - EMA (European Medicines Agency)

csl behring gmbh - alpha1-proteinase inhibitor (human) - genetic diseases, inborn, lung diseases - antihemorrhagics, - respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes pizz, piz(null), pi(null,null), pisz). patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (fev1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.,